Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates

Haemophilia

Volumn 10, Issue 5, 2004, Pages 459-469

  Lin, Y ^a   Yang, X ^a   Chevrier, M C ^b   Craven, S ^c   Barrowcliffe, T W ^d   Lemieux, R ^b   Ofoso, Frederick A ^a,c  

^a MCMASTER UNIVERSITY   (Canada)

^b HÉMA QUÉBEC   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

^d NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Enzyme linked immunosorbent assay; Factor VIII; Hemophilia A; von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; IMMUNOGLOBULIN G; PLASMA PROTEIN; POLYCLONAL ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ANTIBODY PRODUCTION; ARTICLE; BLEEDING; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL FILTRATION CHROMATOGRAPHY; GENETIC SUSCEPTIBILITY; HEMOPHILIA A; HUMAN; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; RISK ASSESSMENT; SIDE EFFECT;

BLOTTING, WESTERN; DRUG INTERACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; PLASMA; VON WILLEBRAND FACTOR;

EID: 4844227035     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2004.00957.x     Document Type: Article

References (28)

1. Wood WI, Capon DJ, Simonsen CC et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-7.
2. Toole JJ, Knopf JL, Wozney JM et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-7.
3. Vehar GA, Keyt B, Eaton D et al. Structure of human factor VIII. Nature 1984; 312: 337-42.
4. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-12.
5. Andersson LO, Forsman N, Huang K et al. Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma. Proc Natl Acad Sci USA 1986; 83: 2979-83.
6. Fay PJ, Anderson MT, Chavin SI, Marder VJ. The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim Biophys Acta 1986; 871: 268-78.
7. Hoyer LW. The factor VIII complex: structure and function. Blood 1981; 58: 1-13.
8. Koedam JA, Hamer RJ, Beeser-Visser NH, Bouma BN, Sixma JJ. The effect of von Willebrand factor on activation of factor VIII by factor Xa. Eur J Biochem 1990; 189: 229-34.
9. Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82: 1236-43.
10. Fay PJ, Coumans JV, Walker FJ. Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem 1991; 266: 2172-7.
11. Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263: 10451-5.
12. Vlot AJ, Koppelman SJ, van den Berg MH, Bouma BN, Sixma JJ. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 1995; 85: 3150-7.
13. Saenko EL, Loster K, Josic D, Sarafanov AG. Effect of von Willebrand Factor and its proteolytic fragments on kinetics of interaction between the light and heavy chains of human factor VIII. Thromb Res 1999; 96: 343-54.
14. Lusher JM. First and second-generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Semin Thromb Hemost 2002; 28: 273-6.
15. Polson A. Isolation of IgY from the yolks of eggs by a chloroform polyethylene glycol procedure. Immunol Invest 1990; 19: 253-258.
16. Bazin R, Lemieux R. Increased proportion of B-cell hybridomas secreting monoclonal antibodies of desired specificity in cultures containing hybridoma growth factor (IL-6). J Immunol Methods 1989; 116: 245-54.
17. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
18. Wight J, Paisley S. The epidemiology of inhibitors in hemophilia A: a systematic review. Hemophilia 2003; 9: 418-435.
19. Weiss HJ, Hoyer IW. von Willebrand factor: dissociation from antihemophilic factor procoagulant activity. Science 1973; 182: 1149-51.
20. Sussman II, Rosner W, Weiss HJ. Concentration-dependent dissociation of factor VIII in 1 M NaCl. Am J Physiol 1976; 230: 434-40.
21. Zelechowska MG, van Mourik JA, Brodniewicz-Proba T. Ultrastructural localization of FVIII procoagulant antigen in human liver hepatocytes. Nature 1985; 317: 729-30.
22. Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem 1991; 266: 21948-55.
23. Lee C. The use of the recombinant factor VIII products in previously treated patients with hemophilia A: pharmacokinetics, efficacy, safety and inhibitor development. Semin Thromb Hemost 2002; 28: 241-6.
24. White GC, Courtier S II, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (recombinate) in previously treated patients with hemophilia A. The recombinant previously treated patient study group. Thromb Haemost 1997; 77: 660-7.
25. Dimichele D. Inhibitors: Resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280-7.
26. Scharrer I, Ehrlich HJ. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII. Haemophilia 2001; 7: 346-8.
27. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
28. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients-a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54.